Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

900110

registered interest
date	08/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Autism
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the trends in waiting times for Autism Spectrum Disorder assessments; and if he will make a statement.
tabling member constituency	North West Durham
tabling member printed	Laura Pidcock
uin	141911
answer	answer is ministerial correction date of answer 15/05/2018 answer text <p>The Department has made no recent assessment of the trends in waiting times for autism spectrum disorder assessments.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) guidelines recommend that the time from a referral to a first appointment is no longer than three months.</p><p> </p><p>The latest available data for the country as a whole is available in Public Health England’s report, ‘Autism Self-Assessment Exercise 2016 Detailed report and thematic analyses’ (published June 2017). The report states that 33 local authorities (22%) reported already meeting the NICE recommended waiting times, 35 (23%) anticipated meeting NICE recommended waiting times by March 2017 and to be able to sustain this thereafter and 66 (43%) did not anticipate being able to reach NICE recommended waiting times sustainably by March 2017. 18 local authorities did not respond to the relevant question.</p><p> </p><p>Collection of national waiting times data from referral to a first appointment and on to a diagnosis if one is given, began in April this year. Results will be published in due course.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/05/2018 10:31:57 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4665 label Biography information for Laura Pidcock

896246

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Costs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 March to Question 131104 on Drugs: Costs, what assessment he has made of the cost of branded medicines (a) to the NHS and (b) in comparison with the health systems in other EU countries.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	140557
answer	answer is ministerial correction date of answer 09/05/2018 answer text <p>National Health Service spend on branded medicines during 2015-2016 was approximately £11.2 billion. The Pharmaceutical Price Regulation Scheme (PPRS) supports the NHS to improve patient access to clinically and cost effective medicines through the rigorous National Institute for Health and Care Excellence appraisal process, which plays important role in helping to ensure the best outcomes for patients with the resources available. This is coupled with industry making payments on branded medicines sales above an agreed growth cap.</p><p> </p><p>The statutory scheme provides a financial safeguard for the NHS, by providing controls on the costs of branded medicines to the NHS where a company has chosen not to join the PPRS. New regulations came into force on 1 April 2018, which amended the statutory scheme to align it more closely with the 2014 PPRS. In particular, the regulations replaced a system of price cuts with a payment system; the payment percentage introduced – 7.8% - is the same as the 2018 percentage in the PPRS.</p><p> </p><p>The Department does not make a formal assessment of branded medicines expenditure in comparison with other European Union countries, and some of the information necessary to do that is commercially confidential. Participation in the EURIPID pricing project ensures we receive regular information on initiatives across EU countries in relation to branded medicines pricing.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/05/2018 10:45:58 answering member 4067 label Biography information for Steve Brine
tabling member	298 label Biography information for Steve McCabe

896293

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Injuries: Hospital Beds
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on the timetable for the beds being used by non-spinal cord injured patients in the (a) National Spinal Injuries Centre at Stoke Mandeville and (b) Yorkshire Regional Spinal Injuries Centre, Pinderfields to be returned to use by spinal cord injured patients.
tabling member constituency	Wrexham
tabling member printed	Ian C. Lucas
uin	140655
answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>NHS England commissions specialised spinal care from eight centres in England for patients who have suffered a spinal cord injury, totalling 374 beds. The service is managed locally and delivered by spinal cord injury specialists, both within the spinal cord injury centres and as outreach to acute hospitals and following discharge for transition and reintegration into the community.</p><p> </p><p>NHS England’s national team has advised that it is not aware of any intelligence to suggest that a spinal cord injury patient has been denied a specialist bed during the winter period due to its use by a non-spinal cord injury patient.</p><p> </p><p>Information concerning the number and proportion of spinal cord injured patients who are treated in a specialist spinal cord injury centre for their initial rehabilitation relative to those who receive that rehabilitation in a different clinical or other setting is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 140656 question first answered 14/05/2018 15:43:01 answering member 4067 label Biography information for Steve Brine
tabling member	1470 label Biography information for Ian C. Lucas

896405

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Leukaemia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on the need for (a) new treatment options to be made available on the NHS for patients with acute myeloid leukaemia and (b) open and ongoing dialogue with pharmaceutical companies throughout the technology appraisal process to ensure that patients are able to access new and innovative medicines on the NHS.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	140615
answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>Departmental Ministers and officials routinely discuss a range of issues with the National Institute for Health and Care Excellence (NICE), including in relation to appraisals of new cancer drugs and dialogue with pharmaceutical companies.</p><p> </p><p>The Department has asked NICE to develop technology appraisal guidance for the National Health Service on the use of a number of potential new medicines for use in the treatment of acute myeloid leukaemia. NICE is carrying out these appraisals under the arrangements for the assessment and adoption of new cancer drugs introduced in 2016 that are designed to ensure that promising new cancer drugs can be made available to patients as quickly as possible.</p><p> </p><p>The Pharmaceutical Price Regulation Scheme (PPRS) sets out a range of measures to facilitate rapid access to cost-effective medicines, including the option for companies to propose a patient access scheme as part of a NICE appraisal. Informal discussions have already begun with industry regarding future medicines pricing arrangements, which will replace the current PPRS from 2019.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/05/2018 15:45:05 answering member 4067 label Biography information for Steve Brine
tabling member	1383 label Biography information for Mark Tami

896431

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Compulsorily Detained Psychiatric Patients
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 May 2018 to Question 138009, what estimate he has made of the cost of answering that Question; and if he will publish a breakdown of those costs.
tabling member constituency	Shipley
tabling member printed	Philip Davies
uin	140692
answer	answer is ministerial correction date of answer 10/05/2018 answer text <p>In order to answer the question it would require a significant amount of new analysis to interrogate the Mental Health Services Data Set. NHS Digital has determined the cost of answering the Question to be approximately £2,854, consisting of £2,650 for the cost of producing the analysis, checking and formatting the reply, and £204 for the cost of manager validation and internal clearances.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 10/05/2018 14:28:20 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1565 label Biography information for Sir Philip Davies

896536

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on contacting women who have not received a breast cancer screening since 2010.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	140735
answer	answer is ministerial correction date of answer 09/05/2018 answer text <p>The United Kingdom National Screening Committee has produced reviews on the effectiveness of screening for the following cancers; the breast, bowel, cervical screening programmes are effective. Prostate, lung, ovary, mouth, gastric, and bladder are not recommended as there is not enough evidence to suggest that they are effective. Further information is available at the following link:</p><p> </p><p><a href="https://legacyscreening.phe.org.uk/screening-recommendations.php" target="_blank">https://legacyscreening.phe.org.uk/screening-recommendations.php</a></p><p> </p><p>Public Health England will contact all the women affected living within the UK who are registered with a general practitioner before the end of May with the first 65,000 letters going out this week.</p><p> </p><p>The breast screening programme was started in 1988 and rolled out over three years. It originally invited women aged 50 to 64. Following pilots in the late 1990s screening was extended for women aged up to 70 between 2001 and 2006 in line with the National Health Service Cancer Plan. The Cancer Reform Strategy (2007) outlined plan to extend the age range of breast screening to offer screening to all women aged 47-73 years in England from 2012. However, to gather as much evidence as possible on screening the extended age ranges, the decision was taken for the extension to become a randomised controlled trial (AgeX). Further information is available at the following link:</p><p> </p><p><a href="http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/Browsable/DH_4990751" target="_blank">http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/Browsable/DH_4990751</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 140734 140736 question first answered 09/05/2018 10:51:07 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

896562

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 April 2018 to Question 135263 on HIV Infection, what steps his Department has taken to in response to the recommendations in the British HIV Association National Audit 2015; and if he will make a statement on the use of health assessments for people living with HIV.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Luke Pollard
uin	140871
answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>NHS England is responsible for commissioning high quality HIV treatment and care, and therefore for addressing recommendations from the British HIV Association national audit 2015. NHS England published a service specification ‘Specialised HIV Services for Adults (Outpatient and Inpatient Services)’ in 2013. The aim is to provide specialist assessment and ongoing management of HIV and associated conditions in order to support patients to stay well (reduced mortality and morbidity) and to reduce the risk of onward transmission of HIV. The service aims to ensure that the outcomes, wellbeing and quality of life of adults with HIV are maximised. Further information is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/05/2018 15:47:46 answering member 4067 label Biography information for Steve Brine
tabling member	4682 label Biography information for Luke Pollard

896564

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs: Waste Disposal
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the value of unused prescription drugs returned to pharmacies and NHS outlets for disposal in the last 12 months for which figures are available.
tabling member constituency	East Worthing and Shoreham
tabling member printed	Tim Loughton
uin	140545
answer	answer is ministerial correction date of answer 09/05/2018 answer text <p>Information is not held centrally on the value of unused prescription drugs returned to pharmacies and National Health Service outlets for disposal.</p><p> </p><p>The Department commissioned the York Health Economics Consortium and the School of Pharmacy at the University of London to carry out research to determine the scale, causes and costs of waste medicines in England. The report, Evaluation of the Scale, Causes and Costs of Waste Medicines, was published on 23 November 2010. This found that the gross cost of unused prescription medicines in primary and community care in the NHS in England in 2009 was £300 million a year and that up to £150 million of this was avoidable. The report is available at:</p><p> </p><p><a href="http://discovery.ucl.ac.uk/1350234/" target="_blank">http://discovery.ucl.ac.uk/1350234/</a></p><p> </p><p>A number of initiatives have been rolled out which NHS England expects will directly impact on medicines wastage, including the deployment of clinical pharmacists and pharmacy technicians in general practice and also in care homes to undertake medicines reviews; and rolling out dose-banded chemotherapy drugs for cancer. In addition, work to address problematic polypharmacy and ensure appropriate de-prescribing, the establishment of a patient and public medicines adherence campaign and addressing variation through the use of RightCare principles will also contribute to a reduction in medicines waste.</p><p> </p><p>While recognising the importance of reducing medicines wastage from a value for money perspective, the key to securing a reduction in medicines wastage is implementation of the principles of medicines optimisation, ensuring that each patient receives the right medicine, at the right dosage, at the right time.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/05/2018 15:07:54 answering member 4067 label Biography information for Steve Brine
tabling member	114 label Biography information for Tim Loughton

896573

registered interest
date	02/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Consultants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many consultant posts were advertised by discipline at each of the foundation hospitals in 2017; and how many consultants were appointed by discipline at (a) Ainedale General Hospital, (b) Bradford North Infirmary and (c) St Luke's Hospital, Bradford.
tabling member constituency	Keighley
tabling member printed	John Grogan
uin	140572
answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>The data is not available in the format requested.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 14/05/2018 11:30:37 answering member 4095 label Biography information for Steve Barclay
tabling member	382 label Biography information for John Grogan

895209

registered interest
date	01/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prisons: Nurses
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they are taking to improve retention rates amongst nurses across the prison estate.
tabling member printed	Baroness Masham of Ilton
uin	HL7469
answer	answer is ministerial correction date of answer 15/05/2018 answer text <p>It is expected that all prisons have access to a full range of health professionals as per services within the community. Since 2013, NHS England has been responsible for commissioning all healthcare services for prisoners in England.</p><p> </p><p>Recognising that there are particular challenges around recruiting and retaining healthcare staff across the secure and detained estate, NHS England commissioned a review to look at the workforce, market management and recruitment and retention in adult prisons and immigration removal centres in England.</p><p> </p><p>The review findings were shared with the NHS England Health and Justice Clinical Reference Group in November 2017. The review made recommendations on how the prison healthcare market could be better managed, and what could be done to raise the profile of nursing roles, increase the number of qualified nurses and reduce the number of agency staff. An implementation plan is currently being developed to drive forward these recommendations, overseen by the NHS England Health and Justice Clinical Reference Group, working closely with the Royal College of Nursing Professional Lead for Justice and Forensic Nursing and Learning Disability Nursing.</p><p> </p><p>Work is currently underway to identify and collate best practice for inclusion within the plan, which is likely to advocate a comprehensive range of supportive activities that commissioners and providers can use to improve the recruitment, retention and wellbeing of nursing teams. These include strengthening leadership and governance arrangements; removing non-nursing duties from nurses’ roles; improved administrative support; access to technological solutions; enhancements to working environments and improved terms and conditions.</p> answering member printed Lord O'Shaughnessy question first answered 15/05/2018 16:20:40 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1850 label Biography information for Baroness Masham of Ilton